Clinical Outcomes of Patients Receiving Integrated PET/CT-Guided Radiotherapy for Head and Neck Carcinoma
Matthew R. Vernon(Medical College of Wisconsin), Dian Wang(Medical College of Wisconsin), Mohit Maheshwari(Medical College of Wisconsin), Stuart J. Wong(Medical College of Wisconsin), Christopher J. Schultz(The University of Texas MD Anderson Cancer Center), J. Frank Wilson(Medical College of Wisconsin), Becky Massey(Medical College of Wisconsin), Michelle A. Michel(Medical College of Wisconsin), Bruce H. Campbell(Johns Hopkins University)
International Journal of Radiation Oncology*Biology*Physics
February 8, 2008
Cited by 93
Related Papers
Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2004|3.2k
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
|Journal of Clinical Oncology|2013|1.1k
Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma
|New England Journal of Medicine|2016|1k
Primary Central Nervous System Lymphoma: The Memorial Sloan-Kettering Cancer Center Prognostic Model
|Journal of Clinical Oncology|2006|620
Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: Report of Radiation Therapy Oncology Group 93-05 protocol
|International Journal of Radiation Oncology*Biology*Physics|2004|564